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Abstract 
Background: Pharmacokinetics of warfarin has not been described in our population. We derived the 
pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: 
Patients receiving warfarin for at least 6 months were recruited and their demographic characteristics, 
prothrombin time international normalized ratio (PT-INR), warfarin doses and concomitant drugs were 
collected. Using a validated pharmacokinetic-pharmacodynamic model, we predicted maximum plasma 
concentration (Cmax), total clearance (CL), volume of distribution (Vd) and elimination rate (k). Warfarin 
sensitive index (WSI) and warfarin composite measures (WCM) were estimated from the dose and INR 
values. Liver weight was predicted using validated formula. Results: Two-hundred and twenty patients 
were recruited. The following were the predicted pharmacokinetic parameters: Cmax (mg/L) was 5.8 (0.4); k 
(L/day) was 1 (0.1); CL (L/day) was 2.1 (0.2); and Vd (L) was 7.6 (0.2). Patients with Cmax and elimination rate 
outside the mean+1.96 SD had significantly lower WSI and higher WCM. Significant correlations were 
observed between Cmax with CL, Vd, and k of warfarin. Significant correlations were also observed between 
CL and Vd of warfarin with liver weight of the study participants. Conclusion: We predicted 
pharmacokinetic parameters of warfarin from the validated pharmacokinetic-pharmacodynamic model in 
our population. More studies are needed exploring the relationship between various pharmacodynamic 
indices of warfarin and pharmacokinetic parameters of warfarin. 
©2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
Warfarin, an oral anticoagulant, exhibits narrow therapeutic window and poses clinical 
challenges in maintaining appropriate therapeutic effect. Warfarin is metabolized in liver and its 
anticoagulant effect is considered optimum when the prothrombin time international normalized 
ratio (PT-INR) is to be maintained between 2.5 and 3.5 for those undergoing heart valve 
replacements and between 2 and 3 for others [1]. Warfarin is completely absorbed with time to 
maximum concentration of 2-6 hours; volume of distribution (Vd) of 10 L; clearance (CL) of 0.2 
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L/hour; and elimination half-life of 35 hours [2]. Warfarin is a racemic mixture of S- and R-warfarin 
posing challenges in measurements [3]. Pharmacokinetic-pharmacodynamic (PK-PD) relationship 
of warfarin has been well elucidated and therapeutic drug monitoring is carried out by PT-INR 
measurement [4]. Warfarin pharmacokinetics has not been described in our population. Hence, 
we carried out the present study to predict the pharmacokinetic parameters of warfarin from the 
pharmacodynamic variables using a validated PD-PD model.   
Experimental  
Study ethics and design 
The study was retrospective carried out as a part of warfarin pharmacogenomics study after obtaining 
approval from institutional ethics committee and consent from study participants. The present study 
complies with the latest World Medical Association Declaration of Helsinki guidelines. 
Study procedure 
Participants receiving warfarin for at least 6 months were recruited in the present study. Their 
demographics, PT-INR values, dose and frequency of warfarin, and concomitant drugs were obtained. We 
assessed CHA₂DS₂-VASc, HASBLED and SAMe-TT2R2 scores for the study participants [5,6]. Drugs/drug 
classes such as statins, proton pump inhibitors, carbamazepine and amiodarone were categorized as drugs 
with potential interaction with warfarin [7]. We followed National Institute for Health and Care Excellence 
(NICE) guidelines for classifying anticoagulation control into good (TTR ≥ 65 %) and poor (TTR < 65 %) [8]. 
We estimated Warfarin sensitive index (WSI) based on the ratio of PT-INR upon the last dose of warfarin 
[9]. We assessed the difference in PT-INR between the two consequent visits that was squared and divided 
by the time interval in days. This cross product with the average of PT-INR on the visits followed by square 
root of this product provided the INR variability. We log-transformed it to base 10 to obtain log-INR 
variability [10]. Standardized Z scores were obtained for TTR and log-INR variability and warfarin composite 
measure (WCM) was estimated [11]. Liver weight was estimated by using the validated formula: liver 
weight (g) = 218 + body weight (kg) * 12.3 + gender * 51 (Male-1; Female-0) [12]. 
Predicted pharmacokinetic parameters 
We used JPKD software© for estimating pharmacokinetic parameters of warfarin from the validated 






m/k)*(4.368*INR^(0.383)-3.36)))* Cmax *(1-exp((-Cl/V)*Tau/24))*V 
Statistical analysis 
We represented the demographic details using descriptive statistics. Chi-square test for association was 
used for assessing the categorical variables. Numerical variables following the assessment of their 
distributions were tested using Mann-Whitney U test. Correlations between the variables were tested using 
Pearson correlation tests. A p-value of < 0.05 was considered significant. SPSS version 26 (IBM Corp. 
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Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.) was used for 
statistical analysis. Normal distributions were created for each of the key pharmacokinetic parameters and 




Two-hundred and twenty patients were enrolled in this study. Their demographic details are listed in 
Table 1. The concomitant diagnoses in the study participants were as follows: systemic hypertension 
(n=130), diabetes mellitus (n=98), atrial fibrillation (n=85), ischemic heart disease (n=55), thyroid disorders 
(n=24), congestive cardiac failure (n=9) and bronchial asthma (n=15). 




Mean (SD) Cmax (mg/L) amongst the study 
participants was 5.8 (0.4); elimination rate 
(L/day) was 1 (0.1); CL (L/day) was 2.1 (0.2); and 
Vd (L) was 7.6 (0.2). Distributions of the 
pharmacokinetic parameters are depicted in 
Figure 1. Nineteen patients had their Cmax 
outside the mean+1.96 SD and 14 had the same 
for elimination rate. Such patients were 
observed with significantly lower WSI and 
greater WCM (Table 2). For CL, two had their values lower than mean–1.96 SD; and for Vd, two had lower 
than mean–2 SD, and four more than mean+2 SD. Due to the number constraints, we could not analyze the 
differences in any of the variables for CL and Vd of warfarin.   
No significant differences were observed between the predicted pharmacokinetic parameters across the 
age groups (Figure 2). Similar values were obtained for males [Cmax (mg/L – 5.8 (0.4); k (per day) – 1 (0.1); CL 
(L/day) – 2.1 (0.2); and Vd (L) – 7.6 (0.2)] and females [Cmax (mg/L – 5.8 (0.4); k (per day) – 1 (0.05); CL 
(L/day) – 2.1 (0.2); and Vd (L) – 7.7 (0.2)]. Significant correlations were observed between Cmax and CL (r = -
0.4; p=0.0001), Vd (r = 0.28; p = 0.004) and k (r = 0.8; p = 0.0001) (Figure 3). 
 
Association between liver weights and predicted pharmacokinetic parameters 
Scatterplot revealed significant correlations between warfarin CL (r=0.2; p=0.04) and Vd (r= -0.2; p=0.03) 





 66.6 (13.4) 
Male : Female 1 : 1 
Body weight (kg)
$
 75.2 (18.1) 
Predicted liver weight (g)
 $
 1148 (265) 
CHA2DS2-VASc score
$
 3.7 (1.5) 
HASBLED score
$
 2.3 (1.1) 
SAMe-TT2R2 score
$
 1.4 (0.6) 
Duration of warfarin (days) 
$
 1027 (572.2) 
Warfarin sensitive index 
$
 0.7 (0.4) 
Log INR variability 
$
 -0.84 (0.2) 
Warfarin composite measure score 
$
 -1.3 (1.2) 
Number of patients with drugs with 
potential interaction [n (%)] 
136 (61.8) 
$ - Represented in mean (SD)  




Figure 1. Distribution of pharmacokinetic parameters in the study population. (A) Distribution of Cmax (mg/L); 
(B) elimination rate (per day); (C) clearance (L/day); (D) volume of distribution (L) in the study population 
 
Table 2. Comparison of characteristics between those within and outside 95% of normal distribution curves in the 
study population 
Variables 
Cmax (mg/L) Elimination rate (per day) 
Within 95% of 
ND (n= 201) 
Outside 95% 
of ND (n= 19) 
P-values 
Within 95% of 
ND (n=206) 
Outside 95% 









75 (18.4) 77.6 (14.1) 0.4 72.8 (19) 81.6 (12) 0.2 
TTR (%) 
$
 65.6 (17.2) 64.7 (16.4) 0.6 65.7 (16.1) 65 (21) 1 
WSI 
$





-0.8 (0.2) -0.9 (0.2) 0.06 -0.8 (0.2) -0.9 (0.2) 0.06 
WCM 
$




[n (%)]  
123 (61.2) 12 (63.2) 0.9 135 (65.5) 8 (57.1) 0.5 
Y-Young; M-Middle-aged & older adults; E – Elderly; VE – Very elderly; TTR – Time spent in therapeutic range; WSI – warfarin 
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Figure 2. Predicted pharmacokinetic parameters of warfarin in different age groups. (A) Predicted Cmax 
(mg/L); (B) predicted elimination (L/day); (C) predicted clearance (L/day); (D) predicted Vd (L) in different age 
groups. 
 
Figure 3. Scatter plot matrix between the pharmacokinetic parameters and the liver weight. Warfarin 
clearance and volume of distribution were significantly correlated with the weight of the liver. CL- clearance; 
k – elimination rate; Vd – volume of distribution 
(A) (B) 
(C) (D) 
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Discussion 
We evaluated the pharmacokinetic parameters of warfarin using validated PK-PD model in our 
population. Two-hundred and twenty patients were recruited. The following were the predicted 
pharmacokinetic parameters: Cmax (mg/L) was 5.8 (0.4); elimination rate (L/day) was 1 (0.1); CL (L/day) was 
2.1 (0.2); and Vd (L) was 7.6 (0.2). Patients with Cmax and elimination rate outside the mean+1.96 SD had 
significantly lower WSI and higher WCM. Significant correlations were observed between Cmax with CL, Vd, 
and k of warfarin. Significant correlations were also observed between CL and Vd of warfarin with liver 
weight of the study participants.      
The pharmacokinetic parameters of racemic warfarin observed in the present study is like other 
populations [14]. Although it would be better to measure S- and R- warfarin concentrations, the clinical 
relevance of estimating enantiomers is limited. Ours is the first study exploring the relationship between 
pharmacokinetic parameters and WSI and WCM (the pharmacodynamic parameters). Lower WSI is 
corroborated with warfarin resistance. Genotyping of vitamin K epoxide reductase complex in our 
population might provide a clue towards the prevalence and depth of warfarin resistance. The present 
study is also the first in exploring the relationship between liver weight and pharmacokinetic parameters of 
warfarin. Though, liver weight has been argued to be a better corroborator of pharmacokinetic parameters 
in children, [15] its relationship in adults has not been studied. 
The study is limited in not validating the pharmacokinetic parameters using real-time measurements of 
plasma warfarin concentrations. To conclude, we predicted pharmacokinetic parameters of warfarin from 
the validated pharmacokinetic-pharmacodynamic model in our population. More studies are needed 
exploring the relationship between various pharmacodynamic indices of warfarin and pharmacokinetic 
parameters of warfarin. 
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